Malaysia
Search
Sign In
Change Password
Points
Sign Out
The EGFR tyrosine kinase inhibitor (TKI) dacomitinib showed superior overall survival (OS) vs gefitinib in patients with treatment-naïve EGFR-positive non-small-cell lung cancer (NSCLC) in the final analysis of the ARCHER 1050 study.
Children who undergo adenoidectomy, tonsillectomy, or both (adenotonsillectomy) within the first 9 years of life may have an elevated long-term risk of respiratory, allergic, or infectious diseases, results from a Denmark-based study show.
Patients with chronic obstructive pulmonary disease (COPD) and chronic hypoxemic respiratory failure experienced fewer exacerbations and symptoms when treated with humidified high-flow therapy via a nasal cannula (HFNC) in addition to long-term oxygen therapy (LTOT) compared with those treated with LTOT alone, according to a study from Denmark.
Prescribing antibiotics despite no indication of infection to patients hospitalized with asthma was associated with longer hospital stay, a higher risk of antibiotic-related diarrhoea, and elevated hospitalization costs, according to a study presented at the recent American Thoracic Society conference (ATS 2018).
Genetic testing has changed the landscape of lung cancer and every patient needs to undergo testing, says a specialist.
Prescribing antibiotics despite no indication of infection to patients hospitalized with asthma was associated with longer hospital stay, a higher risk of antibiotic-related diarrhoea, and elevated hospitalization costs, according to a study presented at the recent American Thoracic Society conference (ATS 2018).
Dupilumab, the fully human anti-interleukin-4 receptor α monoclonal antibody indicated for the treatment of atopic dermatitis, appeared to improve lung function, reduce exacerbations, and decrease oral corticosteroid use in individuals with moderate-to-severe asthma, according to two phase III trials presented at ATS 2018.
De-escalating treatment from triple therapy (LABA*/LAMA**/inhaled corticosteroid [ICS]) to dual bronchodilator therapy (indacaterol/glycopyrronium) did not increase exacerbation rate, though there was a minor decrease in lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) with infrequent exacerbations, according to results of the SUNSET*** trial presented at the recent American Thoracic Society conference (ATS 2018).
